What is HC Wainwright’s Forecast for LifeMD FY2025 Earnings?

LifeMD, Inc. (NASDAQ:LFMD) – Equities researchers at HC Wainwright increased their FY2025 EPS estimates for LifeMD in a research report issued to clients and investors on Wednesday, November 19th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.04) for the year, up from their prior estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q4 2025 earnings at $0.10 EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($1.01) EPS.

Several other equities research analysts have also issued reports on the company. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday. Mizuho dropped their price target on LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, November 19th. BTIG Research cut their price objective on LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. KeyCorp lowered their target price on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, LifeMD has a consensus rating of “Hold” and an average target price of $9.43.

LifeMD Price Performance

LFMD opened at $3.85 on Monday. The firm has a market capitalization of $185.34 million, a P/E ratio of -22.65 and a beta of 1.57. LifeMD has a one year low of $3.43 and a one year high of $15.84. The company has a fifty day moving average price of $5.88 and a 200-day moving average price of $8.60.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Insider Activity at LifeMD

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider directly owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its position in LifeMD by 148.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after purchasing an additional 2,185 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after buying an additional 2,452 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of LifeMD by 1,004.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company’s stock worth $70,000 after buying an additional 4,703 shares during the period. Quarry LP bought a new stake in shares of LifeMD in the 3rd quarter valued at about $52,000. Finally, CWM LLC boosted its holdings in LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after acquiring an additional 1,351 shares during the period. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.